FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034385594> ?p ?o ?g. }

• W2034385594 endingPage "343" @default.
• W2034385594 startingPage "335" @default.
• W2034385594 abstract "Background. Ritonavir, a potent antiretroviral protease inhibitor, has been approved for the treatment of adults and children with human immunodeficiency virus (HIV) infection. In a phase I/II study, we assessed the safety, tolerability, and pharmacokinetic profile of the oral solution of ritonavir in HIV-infected children and studied the preliminary antiviral and clinical effects. Methods. HIV-infected children between 6 months and 18 years of age were eligible. Four dose levels of ritonavir oral solution (250, 300, 350, and 400 mg/m2 given every 12 hours) were evaluated in two age groups (≤2 years, &gt;2 years). Ritonavir was administered alone for the first 12 weeks and then in combination with zidovudine and/or didanosine. Clinical and laboratory parameters were monitored every 2 to 4 weeks. Results. A total of 48 children (median age, 7.7 years; range, 0.5 to 14.4 years) were included in this analysis. Dose-related nausea, diarrhea, and abdominal pain were the most common toxicities and resulted in discontinuation of ritonavir in 7 children. Ritonavir was well absorbed at all dose levels, and plasma concentrations reached a peak 2 to 4 hours after a dose. CD4 cells counts increased by a median of 79 cells/mm3 after 4 weeks of monotherapy and were maintained throughout the study. Plasma HIV RNA decreased by 1 to 2 log10 copies/mL within 4 to 8 weeks of ritonavir monotherapy, and this level was sustained in patients enrolled at the highest dose level of 400 mg/m2 for the 24-week period. Conclusions. The oral solution of ritonavir has potent antiretroviral activity as a single agent and is relatively well tolerated by children when administered alone or in combination with zidovudine or didanosine." @default.
• W2034385594 created "2016-06-24" @default.
• W2034385594 creator A5000083226 @default.
• W2034385594 creator A5001384011 @default.
• W2034385594 creator A5006249476 @default.
• W2034385594 creator A5008898573 @default.
• W2034385594 creator A5020280401 @default.
• W2034385594 creator A5021474363 @default.
• W2034385594 creator A5025036510 @default.
• W2034385594 creator A5026165592 @default.
• W2034385594 creator A5034382194 @default.
• W2034385594 creator A5035283039 @default.
• W2034385594 creator A5040709669 @default.
• W2034385594 creator A5044239219 @default.
• W2034385594 creator A5053127256 @default.
• W2034385594 creator A5053917846 @default.
• W2034385594 creator A5061133601 @default.
• W2034385594 creator A5061693223 @default.
• W2034385594 creator A5062384041 @default.
• W2034385594 creator A5064611705 @default.
• W2034385594 creator A5071736558 @default.
• W2034385594 creator A5076089404 @default.
• W2034385594 creator A5078392914 @default.
• W2034385594 creator A5083719333 @default.
• W2034385594 date "1998-03-01" @default.
• W2034385594 modified "2023-10-17" @default.
• W2034385594 title "A Phase I/II Study of the Protease Inhibitor Ritonavir in Children With Human Immunodeficiency Virus Infection" @default.
• W2034385594 cites W1501333446 @default.
• W2034385594 cites W1524784524 @default.
• W2034385594 cites W1567068711 @default.
• W2034385594 cites W1618865275 @default.
• W2034385594 cites W1921702285 @default.
• W2034385594 cites W1966624986 @default.
• W2034385594 cites W1973696741 @default.
• W2034385594 cites W1983223527 @default.
• W2034385594 cites W2011630381 @default.
• W2034385594 cites W2012139740 @default.
• W2034385594 cites W2022098233 @default.
• W2034385594 cites W2025152688 @default.
• W2034385594 cites W2041415251 @default.
• W2034385594 cites W2055231039 @default.
• W2034385594 cites W2057023456 @default.
• W2034385594 cites W2057481372 @default.
• W2034385594 cites W2057865208 @default.
• W2034385594 cites W2095886530 @default.
• W2034385594 cites W2097916721 @default.
• W2034385594 cites W2109757270 @default.
• W2034385594 cites W2130082288 @default.
• W2034385594 cites W2142997299 @default.
• W2034385594 cites W2327723086 @default.
• W2034385594 cites W2338548517 @default.
• W2034385594 cites W2339057709 @default.
• W2034385594 cites W2339827976 @default.
• W2034385594 cites W39537358 @default.
• W2034385594 doi "https://doi.org/10.1542/peds.101.3.335" @default.
• W2034385594 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9480994" @default.
• W2034385594 hasPublicationYear "1998" @default.
• W2034385594 type Work @default.
• W2034385594 sameAs 2034385594 @default.
• W2034385594 citedByCount "85" @default.
• W2034385594 countsByYear W20343855942012 @default.
• W2034385594 countsByYear W20343855942013 @default.
• W2034385594 countsByYear W20343855942016 @default.
• W2034385594 countsByYear W20343855942017 @default.
• W2034385594 crossrefType "journal-article" @default.
• W2034385594 hasAuthorship W2034385594A5000083226 @default.
• W2034385594 hasAuthorship W2034385594A5001384011 @default.
• W2034385594 hasAuthorship W2034385594A5006249476 @default.
• W2034385594 hasAuthorship W2034385594A5008898573 @default.
• W2034385594 hasAuthorship W2034385594A5020280401 @default.
• W2034385594 hasAuthorship W2034385594A5021474363 @default.
• W2034385594 hasAuthorship W2034385594A5025036510 @default.
• W2034385594 hasAuthorship W2034385594A5026165592 @default.
• W2034385594 hasAuthorship W2034385594A5034382194 @default.
• W2034385594 hasAuthorship W2034385594A5035283039 @default.
• W2034385594 hasAuthorship W2034385594A5040709669 @default.
• W2034385594 hasAuthorship W2034385594A5044239219 @default.
• W2034385594 hasAuthorship W2034385594A5053127256 @default.
• W2034385594 hasAuthorship W2034385594A5053917846 @default.
• W2034385594 hasAuthorship W2034385594A5061133601 @default.
• W2034385594 hasAuthorship W2034385594A5061693223 @default.
• W2034385594 hasAuthorship W2034385594A5062384041 @default.
• W2034385594 hasAuthorship W2034385594A5064611705 @default.
• W2034385594 hasAuthorship W2034385594A5071736558 @default.
• W2034385594 hasAuthorship W2034385594A5076089404 @default.
• W2034385594 hasAuthorship W2034385594A5078392914 @default.
• W2034385594 hasAuthorship W2034385594A5083719333 @default.
• W2034385594 hasConcept C112705442 @default.
• W2034385594 hasConcept C126322002 @default.
• W2034385594 hasConcept C142462285 @default.
• W2034385594 hasConcept C159047783 @default.
• W2034385594 hasConcept C197934379 @default.
• W2034385594 hasConcept C2777210460 @default.
• W2034385594 hasConcept C2777447569 @default.
• W2034385594 hasConcept C2778375690 @default.
• W2034385594 hasConcept C2778715236 @default.
• W2034385594 hasConcept C2779298103 @default.
• W2034385594 hasConcept C2779802037 @default.

• next